There Is No FDA-Approved Drug for PCOS. Here's What the Research Says We Should Be Using.
Polycystic ovary syndrome affects approximately 1 in 10 women of reproductive age. It is the most common endocrine disorder in women. It drives infertility, metabolic disease, type 2 diabetes, cardiovascular risk, anxiety, depression, and a relentless daily burden of symptoms — irregular periods, hair loss, acne, weight gain that doesn't respond to effort, and a medical system that often dismisses all of it.
And yet, there is not a single FDA-approved medication specifically indicated for PCOS. Not one.
Every medication used to treat PCOS — metformin, spironolactone, oral contraceptives — is prescribed off-label. Borrowed from other conditions. Repurposed because no one has funded the large, definitive trials required to make any of them official for PCOS.
That is not a scientific failure. It is a funding priority failure. And it has consequences for millions of women every day.
What "Off-Label" Actually Means
Before we go further, I need to address something I hear constantly from patients: the fear that off-label means experimental, unproven, or unsafe. It doesn't.
Off-label prescribing means that the FDA has not granted a formal indication for a drug in a specific condition — not that the drug doesn't work, not that it hasn't been studied, and not that prescribing it is inappropriate. It means the pharmaceutical company that manufactures the drug has not submitted the application and funded the trials to obtain that specific approval.
Off-label prescribing is legal, common, and standard of care across medicine. It is the backbone of oncology, psychiatry, pediatrics — and women's health. The majority of treatments used for reproductive and hormonal conditions in women are prescribed off-label, precisely because the research infrastructure for women's health has been systematically underfunded for decades. When I prescribe a GLP-1 receptor agonist for PCOS, I am not guessing. I am following the evidence. And the evidence is growing fast.
GLP-1 Receptor Agonists and PCOS: What the Research Shows
GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — work by mimicking a naturally occurring gut hormone that regulates insulin secretion, appetite, gastric emptying, and inflammation. They were developed for type 2 diabetes and later approved for obesity. But their mechanism of action makes them extraordinarily relevant to PCOS, a condition defined at its core by insulin resistance and its downstream hormonal and metabolic consequences.
Here is what the research shows:
Insulin resistance improves. Insulin resistance is the root driver of most PCOS pathology — it drives androgen excess, anovulation, and the metabolic complications that accumulate over time. GLP-1s directly improve insulin sensitivity through multiple mechanisms, including enhanced glucose-dependent insulin secretion and reduced hepatic glucose production. Multiple studies have demonstrated significant reductions in fasting insulin and HOMA-IR in women with PCOS on GLP-1 therapy.
Androgen levels fall. Elevated androgens — testosterone, DHEA-S, androstenedione — cause the acne, hirsutism, and hair thinning that characterize PCOS. As insulin resistance improves on GLP-1 therapy, ovarian androgen production decreases. Studies consistently show reductions in free and total testosterone in women with PCOS treated with GLP-1 agonists.
Menstrual cycles regulate. Anovulation — the failure to ovulate — is one of the defining features of PCOS and the primary driver of infertility. Insulin-driven androgen excess disrupts the hormonal cascade needed for normal follicular development and ovulation. As GLP-1s address the underlying metabolic dysfunction, ovulation resumes. Women who had not had a regular cycle in years start cycling again.
Inflammation decreases. PCOS is a pro-inflammatory condition. Elevated C-reactive protein and other inflammatory markers are common, and chronic low-grade inflammation contributes to both the hormonal and cardiovascular complications of the condition. GLP-1s have direct anti-inflammatory properties, independent of weight loss.
Visceral fat — the most metabolically dangerous fat — decreases preferentially. Women with PCOS tend to accumulate visceral adiposity at higher rates than women without PCOS, even at the same BMI. Visceral fat is far more metabolically active and damaging than subcutaneous fat. GLP-1s produce preferential reductions in visceral fat, directly addressing one of the most dangerous features of the PCOS metabolic phenotype.
The 2025 RCT: Semaglutide Outperforms Metformin Across the Board
The most rigorous recent data comes from a prospective randomized controlled trial published in Reproductive Biology and Endocrinology in 2025. Researchers enrolled 100 overweight or obese women with PCOS diagnosed by Rotterdam criteria and randomized them to 16 weeks of either metformin monotherapy or combination therapy with semaglutide plus metformin. PubMed Central
The results were unambiguous.
The combination group lost an average of 6.09 kg over 16 weeks, compared to 2.25 kg in the metformin-only group. The semaglutide group also showed significantly greater reductions in BMI, waist-to-hip ratio, testosterone, visceral adiposity index, and C-reactive protein — as well as higher rates of menstrual cycle recovery. BioMed Central
But the finding that stopped me in my tracks was this: in the follow-up period from weeks 16 to 40, after semaglutide was discontinued and both groups returned to metformin only, the combination group had a natural pregnancy rate of 35% compared to 15% in the metformin-only group. BioMed Central
Read that again. A 35% natural pregnancy rate versus 15% — in women who had been anovulatory. That is more than double. From 16 weeks of adding semaglutide to metformin. This is not a marginal finding. This is a clinically meaningful difference in one of the outcomes that matters most to my patients.
A separate RCT published in Endocrine Practice compared oral semaglutide plus metformin to myoinositol plus metformin. Semaglutide plus metformin produced significantly greater reductions in cycle length and HOMA-IR compared to myoinositol plus metformin, along with more significant weight loss — making it the first RCT to compare these two commonly used approaches head to head. Endocrine Practice
So Why Doesn't It Have an FDA Indication?
This is the question I get asked most, and the answer is important to understand. FDA drug approvals are not granted automatically when evidence accumulates. A drug company must proactively apply for an indication, submit a formal New Drug Application or supplemental NDA, and fund the clinical trial infrastructure required to support it. That process costs hundreds of millions of dollars. Companies pursue it when the financial return justifies the investment.
The GLP-1 manufacturers — Novo Nordisk and Eli Lilly — have indications for type 2 diabetes and obesity. Those are enormous, lucrative markets. A PCOS indication would expand prescribing access and potentially reduce off-label barriers, but the incentive structure does not compel anyone to pursue it on a particular timeline.
Meanwhile, PCOS affects tens of millions of women. Those women are navigating insurance denials, prior authorization battles, and conversations with providers who may be unfamiliar with the evolving data. The absence of an official indication has real downstream consequences for access.
This is not new. It is the same story metformin has been living for decades. Metformin has robust evidence for PCOS going back to the 1990s. It is still off-label. Spironolactone has been used for PCOS-related androgen excess for decades. Still off-label. The pill is used to manage PCOS symptoms in millions of women every year. Off-label.
Women's health has historically been treated as a niche market rather than a medical priority. The result is a condition affecting 1 in 10 women that still has no dedicated pharmacologic approval after 60 years of medical literature.
What This Means for My Patients
I am an endocrinologist and obesity medicine specialist. I am also a Menopause Society Certified Practitioner who sees the full arc of women's hormonal health — from PCOS in the reproductive years to perimenopause, osteoporosis, and metabolic disease in the decades beyond.
What I see consistently is that PCOS is undertreated and misunderstood — often managed symptomatically for years without addressing the underlying insulin resistance and metabolic dysfunction that drives it.
GLP-1 receptor agonists represent a genuine inflection point in PCOS management. Not because they are a cure, and not because every woman with PCOS needs them — but because they address the root biology of the condition in a way that no other class of medication currently does. They improve insulin sensitivity, reduce androgens, restore ovulation, decrease inflammation, and produce clinically meaningful improvements in the outcomes that matter most to patients: cycles, fertility, weight, energy, and quality of life.
I use them. I stand behind the evidence. And I am not waiting for an FDA label that should have existed years ago.
The Bottom Line
If you have PCOS and you have been told that GLP-1s "aren't approved" for your condition — that is technically accurate and also deeply incomplete. The absence of an indication reflects a funding gap, not an evidence gap.
You deserve a physician who knows the difference.
If you want to know whether a GLP-1 is appropriate for your PCOS, I am happy to talk. My practice is built on direct access, longer visits, and individualized care — because your hormones deserve more than a 10-minute appointment and a handout.